PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce that it was selected by Calliditas Therapeutics for the exclusive distribution of TARPEYO® (budesonide) delayed release capsules TARPEYO® (is the first FDA-approved treatment to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN).1 Primary […]